TREMFYA® is the first FDA-approved medication of its kind to selectively block IL-23 for adults with moderate to severe plaque psoriasis
TREMFYA® is the first FDA-approved medication of its kind to selectively block IL-23
UNCOVER CLEARER SKIN
THAT CAN LAST
THAT CAN LAST
In clinical studies at week 16, 7 out of 10 patients with moderate to severe plaque psoriasis saw 90% clearer skin. In a clinical study, nearly 9 out of 10 patients who saw 90% clearer skin at week 28 maintained it at week 48. Individual results may vary.
THE FIRST STEP TO CLEARER SKIN:
TELL IT LIKE IT IS
A candid conversation with your dermatologist about how your moderate to severe plaque psoriasis is affecting you is the first step to finding the right treatment. Watch the videos below and let a couple of real patients show you how it’s done.
Now that you've heard from other patients,
you can get started with your own
confident conversation.
